# Treatment of Disseminated High Grade Lymphoma

> **NCT00536393** · PHASE2,PHASE3 · COMPLETED · sponsor: **French Innovative Leukemia Organisation** · enrollment: 100 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Doxorubicin pegylated

## Key facts

- **NCT ID:** NCT00536393
- **Lead sponsor:** French Innovative Leukemia Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-10
- **Primary completion:** —
- **Final completion:** 2004-10
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2007-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00536393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00536393, "Treatment of Disseminated High Grade Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00536393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*